MHRA paediatric investigation plan

Vepdegestrant (Vepdegestrant)

MHRA paediatric investigation plan MHRA-101132-PIP01-23 · Waiver

Key facts

PIP number MHRA-101132-PIP01-23
Active substances Vepdegestrant
Therapeutic areas Oncology
Conditions Treatment breast malignant neoplasms
Decision W: decision granting a waiver in all age groups for the listed condition(s).
Published Oct 3, 2024
MHRA record cms.mhra.gov.uk

About MHRA paediatric investigation plans

A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.

Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date:

Browse all MHRA paediatric investigation plans